Allergy Diagnostics Market: Market Size & Forecast 2026

Allergy diagnostics encompasses the tools and procedures used to detect and quantify specific allergens responsible for hypersensitivity reactions in patients. The market spans in-vivo skin prick tests, in-vitro blood-based immunoassays, and emerging molecular diagnostics that target individual allergen components. Rising incidence of allergic rhinitis, asthma, food allergies, and atopic dermatitis across all age groups has substantially broadened the patient base requiring diagnosis.

• •Tests include skin prick tests, blood-based immunoassays, and emerging molecular diagnostics
• •Rising global incidence of allergic rhinitis, asthma, food allergies, and atopic dermatitis broadens the patient base
• •In-vitro blood tests hold the largest segment share due to accuracy and safety

Increasing global prevalence of allergic conditions, driven by urbanization, pollution, dietary shifts, and climate change, directly expands the pool of patients needing diagnosis. Growing awareness among both physicians and patients about the importance of identifying specific allergens for effective management and avoidance strategies has accelerated testing volumes. Advancements in multiplex testing, component-resolved diagnostics, and digital platforms have improved test precision while reducing turnaround times and costs.

• •Urbanization, pollution, dietary changes, and climate change contribute to rising allergy prevalence
• •Increased physician and patient awareness drives higher testing volumes and earlier intervention
• •Multiplex testing and component-resolved diagnostics improve precision while reducing costs

North America currently leads the market, benefiting from high healthcare spending, well-established clinical laboratory infrastructure, and strong awareness of allergy management, while Europe follows with comparable adoption rates and robust regulatory frameworks. The Asia-Pacific region is emerging as the fastest-growing market, propelled by rising allergy prevalence, improving healthcare access, and growing medical expenditure in countries like China and India. By product type, in-vitro blood-based assays represent the dominant segment, while by end-user, clinical laboratories and hospitals account for the majority of testing volume.

• •North America leads with high healthcare spending and established lab infrastructure
• •Asia-Pacific is the fastest-growing region due to rising prevalence and healthcare access expansion
• •Clinical laboratories and hospitals are the dominant end-users, with in-vitro assays the leading product type

What are the recent trends and outlook?

Component-resolved diagnostics using recombinant allergens are gaining adoption, enabling clinicians to distinguish between genuine sensitization and cross-reactive carbohydrate determinants for more precise treatment planning. Multiplex testing arrays that simultaneously screen for dozens or hundreds of allergens are streamlining workflows and reducing per-test costs in high-volume laboratory settings. Home sampling and digital health platforms are beginning to simplify specimen collection and improve patient convenience, particularly in underserved areas.

• •Component-resolved diagnostics using recombinant allergens enable more precise treatment planning
• •Multiplex testing arrays screen for multiple allergens simultaneously, improving laboratory efficiency
• •Home sampling and digital health platforms are emerging to improve patient convenience and access